1. Home
  2. Our People

Ryan L. Steinberg, MD

Clinical Assistant Professor of Urology

Current Positions

  • Clinical Assistant Professor of Urology

Education

  • Bachelor of Science in Bioengineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States
  • MD, Rush University Medical Center, Chicago, Illinois, United States
  • Fellow in Endourology and Minimally Invasive Surgery, University of Texas Southwestern, Dallas, Texas
  • Resident in Urology, University of Iowa, Iowa City, Iowa, United States

Research Interests

  • Development of novel medical devices for the evaluation and treatment of urolithiasis, minimally invasive genitourinary surgery, and urologic oncology surgery
  • Refinement of existing technologies and urologic instrumentation
  • Mechanisms for urolithiasis formation and prevention
  • Evaluation of novel therapeutics to aid with post-ureteroscopy stent discomfort
  • Optimizing existing therapies and developing novel treatments for non-muscle invasive bladder cancer.
  • Novel imaging modalities for stone detection during stone removal surgery

Selected Publications

  • McElree IM, Steinberg RL, Mott SL, Hougen HY, O’Donnell MA, Packiam VT. The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC. Bladder Cancer. 2025;11(2). doi: 10.1177/23523735251324318.
  • McElree IM, Henning GM, Steinberg RL, Hougen HY, Mott SL, O’Donnell MA, Packiam VT. Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter? BJU Int. 2025 Mar 21. doi: 10.1111/bju.16716. Epub ahead of print. PMID: 40118650.
  • Paneque T, Tracy CR, Steinberg RL. Point-of-Care Ultrasound in Urologic Practice and Training. Curr Urol Rep. 2025 Mar 1;26(1):30. doi: 10.1007/s11934-025-01259-3. PMID: 40024964.
  • McElree IM, Packiam VT, Steinberg RL, Hougen HY, Abou Chakra M, Mott SL, O’Donnell MA. Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers (Basel). 2024 Dec 10;16(24):4126. doi: 10.3390/cancers16244126. PMID: 39766026; PMCID: PMC11674833.
  • Livorsi DJ, Packiam VT, Shi Q, Alberding SY, Carter KD, Brown JA, Mason JB, Weiss JP, Steinberg RL. A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeries. Infect Control Hosp Epidemiol. 2024 Nov 7:1-7. doi: 10.1017/ice.2024.172. Epub ahead of print. PMID: 39506499.
  • Kong Z, Johnson BA, Maalouf NM, Nakada SY, Tracy CR, Steinberg RL, Miller N, Antonelli JA, Lotan Y, Pearle MS, Liu YL. Predicting urinary stone recurrence: a joint model analysis of repeated 24-hour urine collections from the MSTONE database. Urolithiasis. 2024 Nov 1;52(1):156. doi: 10.1007/s00240-024-01653-5. PMID: 39485566; PMCID: PMC11530469.
  • Ganesan V, Steinberg RL, Trivedi H, Sorokin I, Johnson BA, Gahan JC. Scheduled intravenous ketorolac is safe and reduces narcotic use after robotic-assisted simple prostatectomy. J Robot Surg. 2024 Oct 3;18(1):358. doi: 10.1007/s11701-024-02068-5. PMID: 39361167.
  • McElree IM, Packiam VT, Steinberg RL, Hougen HY, Mott SL, Abou Chakra M, Zakharia Y, O’Donnell MA. Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers (Basel). 2024 Jul 17;16(14):2561. doi: 10.3390/cancers16142561. PMID: 39061200; PMCID: PMC11274621.
  • Kominsky HD, Dai J, Morgan TN, Garbens A, Steinberg RL, Cadeddu JA. Evaluating acetate as a renoprotective agent following kidney ischemia in a porcine model. J Endourol. 2024 Jul;38(7):701-706. doi: 10.1089/end.2023.0289. Epub 2024 Jun 7. PMID: 38760937.
  • McElree IM, Mott SL, Hougen HY, Packiam VT, O’Donnell MA, Steinberg RL. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ. Urol Oncol. 2024 Jul;42(7):221.e9-221.e16. doi: 10.1016/j.urolonc.2024.03.012. Epub 2024 Apr 11. PMID: 38609747.